Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review.
<h4>Purpose</h4>The effectiveness of immunotherapy for postoperative hepatocellular carcinoma patients is still controversial. To address this issue, we did a systemic review of the literatures and analyzed the data with emphasis on the recurrence and survival.<h4>Methods</h4>...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0042879&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850121731628335104 |
|---|---|
| author | Feng Xie Xinji Zhang Hui Li Tao Zheng Feng Xu Rongxi Shen Long Yan Jiamei Yang Jia He |
| author_facet | Feng Xie Xinji Zhang Hui Li Tao Zheng Feng Xu Rongxi Shen Long Yan Jiamei Yang Jia He |
| author_sort | Feng Xie |
| collection | DOAJ |
| description | <h4>Purpose</h4>The effectiveness of immunotherapy for postoperative hepatocellular carcinoma patients is still controversial. To address this issue, we did a systemic review of the literatures and analyzed the data with emphasis on the recurrence and survival.<h4>Methods</h4>We searched six randomized controlled trials that included adoptive immunotherapy in the postoperative management of hepatocellular carcinoma and compared with non-immunotherapy postoperation. A meta-analysis was carried out to examine one- and 3-year recurrence and survival.<h4>Results</h4>The overall analysis revealed significantly reduced risk of 1-year recurrence in patients receiving adoptive immunotherapy (OR=0.35; 95% CI, 0.17 to 0.71; p=0.003), in that the risk of 3-year recurrence with a pooled OR estimated at 0.31 (95% CI 0.16 to 0.61; p=0.001). However, no statistically significant difference was observed for 3-year survival between groups with adoptive immunotherapy and without adjuvant treatment (OR=0.91; 95% CI, 0.45 to 1.84; P=0.792).<h4>Conclusions</h4>Adjuvant immunotherapy with cytokine induced killer cells or lymphokine activated killer cells may reduce recurrence in postoperative hepatocellular carcinoma patients, but may not improve survival. |
| format | Article |
| id | doaj-art-919dcdb480284dbd93fa6c22e1f1fd88 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-919dcdb480284dbd93fa6c22e1f1fd882025-08-20T02:35:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0178e4287910.1371/journal.pone.0042879Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review.Feng XieXinji ZhangHui LiTao ZhengFeng XuRongxi ShenLong YanJiamei YangJia He<h4>Purpose</h4>The effectiveness of immunotherapy for postoperative hepatocellular carcinoma patients is still controversial. To address this issue, we did a systemic review of the literatures and analyzed the data with emphasis on the recurrence and survival.<h4>Methods</h4>We searched six randomized controlled trials that included adoptive immunotherapy in the postoperative management of hepatocellular carcinoma and compared with non-immunotherapy postoperation. A meta-analysis was carried out to examine one- and 3-year recurrence and survival.<h4>Results</h4>The overall analysis revealed significantly reduced risk of 1-year recurrence in patients receiving adoptive immunotherapy (OR=0.35; 95% CI, 0.17 to 0.71; p=0.003), in that the risk of 3-year recurrence with a pooled OR estimated at 0.31 (95% CI 0.16 to 0.61; p=0.001). However, no statistically significant difference was observed for 3-year survival between groups with adoptive immunotherapy and without adjuvant treatment (OR=0.91; 95% CI, 0.45 to 1.84; P=0.792).<h4>Conclusions</h4>Adjuvant immunotherapy with cytokine induced killer cells or lymphokine activated killer cells may reduce recurrence in postoperative hepatocellular carcinoma patients, but may not improve survival.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0042879&type=printable |
| spellingShingle | Feng Xie Xinji Zhang Hui Li Tao Zheng Feng Xu Rongxi Shen Long Yan Jiamei Yang Jia He Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS ONE |
| title | Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. |
| title_full | Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. |
| title_fullStr | Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. |
| title_full_unstemmed | Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. |
| title_short | Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. |
| title_sort | adoptive immunotherapy in postoperative hepatocellular carcinoma a systemic review |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0042879&type=printable |
| work_keys_str_mv | AT fengxie adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT xinjizhang adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT huili adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT taozheng adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT fengxu adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT rongxishen adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT longyan adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT jiameiyang adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT jiahe adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview |